A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer Vaccine and Therapy
Name
Advanced Materials - 2025 - Huang - A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer.pdf
Description
Published version
Size
3.59 MB
Format
Adobe PDF
Checksum (MD5)
eb2a5e4f353b78f955399e9ec395eb92
Author(s)
Huang, Shengnan
He, Yanpu
Madow, Allison
Peng, Huaiyao
Griffin, Mirielle
Qi, Jifa
Huang, Mantao
Amoroso, Heather
Abrashoff, Riley
Heldman, Nimrod
Date Issued
August 27, 2025
Journal
Advanced Materials
Publisher
Wiley
Citation
S. Huang, Y. He, A. Madow, et al. “ A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer Vaccine and Therapy.” Adv. Mater. 37, no. 43 (2025): e10229.
Version
Final published version
Abstract
Nanovaccines co-assemble antigens and adjuvants to elicit robust immuneresponses but often require complex synthesis and post-modificationprocedures. Here, a programmable nanovaccine platform based on the M13bacteriophage is developed for the scalable production of vaccines andsingle-step modular engineering of adjuvanticity, length, and antigen density.By reprogramming the sequence and size of the noncoding phage genome,the Toll-like receptor 9 activation and the length of the phage are preciselycontrolled. With a novel molecular engineering approach, the antigen densityis tuned from 13.6% to 70.3%. A systematic modulation reveals an optimaladjuvanticity at a constant antigen density for maximum anti-tumor CD8+ Tcell response, and vice versa, using the model antigen SIINFEKL. The M13phage-based nanovaccine induces durable memory immunity lasting over ayear. In addition, a 24-fold increase in neoantigen-specific CD8+ T cellfrequency is achieved when increasing both the adjuvanticity and antigendensity. Furthermore, when combined with anti-PD-1 therapy, the M13phage-based personalized vaccine eradicates established MC-38 tumors in75% of treated animals and they develop 100% resistance against tumorinvasion when challenged 5 months after treatment. These findings establishM13 phage as a powerful and versatile nanovaccine platform withtransformative potential for personalized cancer immunotherapy.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Massachusetts Institute of Technology. Department of Nuclear Science and Engineering
Massachusetts Institute of Technology. Department of Materials Science and Engineering
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1002/adma.202510229
